Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-Protein A monoclonal antibody
- Development stage
- Preclinical
- Lead developer
- ImmunArtes
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Intraperitoneal, Inhalation
01
Overview
ImmunArtes is developing a monoclonal antibody that targets Staphylococcus aureus Protein A (SpA) to prevent and treat infections caused by S. aureus, including methicillin-resistant S. aureus (MRSA). SpA is a key virulence factor that allows the bacteria to evade the host immune system by binding the Fc region of immunoglobulins, thereby preventing proper opsonization and phagocytosis. By neutralizing SpA, this antibody blocks these immune-evasive mechanisms, enhancing opsonophagocytosis and promoting bacterial clearance by innate immune cells. The candidate is currently in preclinical development for life-threatening bloodstream infections such as sepsis and endocarditis. In January 2025, ImmunArtes received $729,000 in funding from CARB-X to support the development of this monoclonal antibody as a preventative measure for high-risk populations.
- Other names
- anti-Protein A / immune-evasion mAbCARB-X-funded monoclonal antibodyanti-SpA mAb
Beyond the preview
Go deeper on anti-Protein A monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-Protein A monoclonal antibody.